NUCIEN PHARMA(SH:688189) Xin Lang Cai Jing·2025-09-09 06:20Core Viewpoint - Nanjing Pharmaceutical experienced a decline of 5.21% on September 9, with a stock price of 12.91 CNY per share and a total market capitalization of 3.543 billion CNY [1] Company Overview - Hunan Nanjing Pharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on December 27, 2006. The company went public on March 26, 2020. Its main business focuses on the research, production, and sales of antiviral and infectious disease prevention drugs, as well as treatments for major diseases such as cardiovascular diseases and diabetes. The revenue composition is entirely from chemical drug formulations, accounting for 100% [1] Shareholder Information - Dazhong Fund's Dazhong Jingheng Mixed A (090019) is among the top ten circulating shareholders of Nanjing Pharmaceutical, holding 2.9738 million shares, unchanged from the previous period, representing 1.08% of the circulating shares. The estimated floating loss today is approximately 2.1114 million CNY [2][4] - Dazhong Jingheng Mixed A was established on June 15, 2012, with a latest scale of 397 million CNY. Year-to-date returns are 39.08%, ranking 1213 out of 8179 in its category; the one-year return is 103.35%, ranking 322 out of 7984; and since inception, the return is 367.01% [2] Fund Manager Information - The fund manager of Dazhong Jingheng Mixed A is Su Bingyi, who has a cumulative tenure of 13 years and 217 days. The total asset scale of the fund is 1.24 billion CNY, with the best fund return during his tenure being 238.45% and the worst being -71.74% [3]